期刊
CURRENT DRUG METABOLISM
卷 19, 期 2, 页码 100-109出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389200218666170925114636
关键词
Microfluidics; blood vessel; 3D bioprinting; drug delivery; nanomedicine; drug screening
资金
- National Cancer Institute of the National Institutes of Health Pathway to Independence Award [K99CA201603]
- Science and Technology Commission of Shanghai Municipality [17JC1400200]
- Lush Prize
- National Natural Science Foundation of China [81301312]
- Chen Guang project - Shanghai Municipal Education Commission
- Shanghai Education Development Foundation [14CG06]
Background: Nanoparticle-based drug delivery systems hold great promise for the treatment of major diseases. However, their slow translation from bench to the clinic posts a concern. It is mainly attributed to the lack of suitable in vitro platforms for rapid and accurate screening of nanomedicine. Recent developments in microfluidic technologies have provided the possibility to reproduce the biomimetic blood vessel microenvironments outside the body, thus offering a convenient means to characterize the in vivo dynamics and biological responses of nanopartides during circulation. Objective: In this review, we discuss the challenges facing the field of nanoparticle drug delivery and highlight the urgent need for construction of blood-vessel-on-a-chip platforms for testing nanomedicine. We subsequently illustrate advances in fabricating various well-controlled blood-vessel-on-a-chip platforms, covering a few examples that have used such models for evaluating nanoparticle behaviors. We then summarize with conclusions and perspectives. Conclusion: We anticipate that, further development of these blood-vessel-on-a-chip platforms with improved biomimetic parameters, tissue specificity, and personalization, will enable their wide applications in drug screening including nanomedicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据